Rapport Therapeutics, INC

Rapport Therapeutics announced second quarter 2026 financial results, highlighting the initiation of its Phase 3 RAP-219 program for focal onset seizures and continued pipeline advancement.

Rapport Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Rapport Therapeutics reported Q1 2026 financials, highlighting progress in its RAP-219 epilepsy program, a new collaboration, and an extended cash runway.

Rapport Therapeutics announced sustained seizure reduction results from the Phase 2a follow-up period of its RAP-219 trial.

Rapport Therapeutics, Inc. filed a prospectus supplement to register the offer and sale of up to $110 million in common stock through sales agents.

Rapport Therapeutics announced accelerated Phase 3 initiation for its epilepsy drug RAP-219, expanded its epilepsy portfolio, and provided pipeline updates.

Rapport Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued investment in R&D and a significant collaboration agreement.

Rapport Therapeutics announces Q1 2026 results, highlighting $20 million collaboration revenue and progress in clinical trials for RAP-219.

Rapport Therapeutics, a clinical-stage biotechnology company, announced positive topline results from its Phase 2a trial of RAP-219 for drug-resistant focal onset seizures, alongside a significant capital raise and continued operating losses.

Rapport Therapeutics reports increased Q2 losses and R&D expenses, with a key pain trial on FDA clinical hold, while advancing its lead epilepsy and bipolar programs.

Rapport Therapeutics announces its Q1 2025 financial results, highlighting progress in clinical trials and research and development programs.

Rapport Therapeutics, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting progress in its clinical programs and a recent FDA clinical hold on a trial for diabetic peripheral neuropathic pain.

Rapport Therapeutics focuses on precision medicines for neurological and psychiatric disorders, advancing its lead candidate for epilepsy while addressing regulatory hurdles in other indications.

Abraham Ceesay, Chief Executive Officer and a Director of Rapport Therapeutics, Inc., sold 51,499 shares of common stock on August 10, 2026.

Abraham Ceesay, Chief Executive Officer and a Director of Rapport Therapeutics, Inc., sold 2,210 shares of common stock on July 27, 2026.

Abraham Ceesay, Chief Executive Officer and a Director of Rapport Therapeutics, Inc., sold 8,210 shares of common stock on July 14, 2026.

Rapport Therapeutics COO Cheryl Gault sold a total of 9,900 shares of common stock across multiple transactions on June 30, 2026, pursuant to a Rule 10b5-1 trading plan.

Rapport Therapeutics CEO Abraham Ceesay sold a significant number of shares under pre-arranged trading plans.

Director John Maraganore was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.

Rapport Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026, to elect directors and ratify auditor appointment.

Rapport Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 17, 2025, with proposals including the election of Class I Directors and ratification of PricewaterhouseCoopers LLP as the independent accounting firm.

Rapport Therapeutics announces its 2025 annual stockholder meeting to be held virtually on June 17, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Rapport Therapeutics files an amendment to its S-1 registration statement, including amended bylaws and details regarding its upcoming IPO and Nasdaq listing.

Rapport Therapeutics, a clinical-stage biopharmaceutical company, has filed for an initial public offering to fund the development of its small molecule medicines for central nervous system disorders.

Sofinnova Venture Partners XI and related entities, including Dr. James I. Healy, reported a decrease in their beneficial ownership of Rapport Therapeutics, Inc. common stock to below 5% due to dilution from the Issuer's recent share sales.

Cormorant Asset Management, LP, through its associated funds, has reported beneficial ownership of 2,657,521 shares, representing 5.56% of the outstanding common stock of Rapport Therapeutics, Inc.

Capital International Investors has disclosed a beneficial ownership of 6.1% in Rapport Therapeutics, Inc., holding 2,921,958 shares.

Cormorant Asset Management, LP and Bihua Chen have reported beneficial ownership of 6.19% of Rapport Therapeutics, Inc. common stock as of March 31, 2026.

Cormorant Asset Management and Bihua Chen report a 6.35% beneficial ownership stake in Rapport Therapeutics, Inc. common stock.

BlackRock, Inc. has reported a 5.03% beneficial ownership stake in Rapport Therapeutics Inc. common stock as of December 31, 2025.

Cormorant Asset Management, LP and Bihua Chen reported a 6.7% beneficial ownership stake in Rapport Therapeutics, Inc. as of September 30, 2025.